XML 148 R126.htm IDEA: XBRL DOCUMENT v2.4.0.8
Segment Information (Details 1) (USD $)
 3 Months Ended 12 Months Ended
Dec. 31, 2013
Sep. 30, 2013
Jun. 30, 2013
Mar. 31, 2013
Dec. 31, 2012
Sep. 30, 2012
Jun. 30, 2012
Mar. 31, 2012
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Geographic information                      
Product, net $ 1,607,100,000 [1],[2] $ 1,453,600,000 $ 1,385,900,000 [3] $ 1,095,800,000 [4] $ 1,074,700,000 [5] $ 1,039,100,000 $ 1,076,800,000 [6] $ 975,400,000 $ 5,542,331,000 $ 4,166,074,000 $ 3,836,117,000
Revenues from unconsolidated joint business                 1,126,000,000 1,137,900,000 996,600,000
Other revenues from external customers 89,400,000 [1],[2] 71,000,000 48,800,000 [3] 54,700,000 [4] 62,300,000 [5] 58,600,000 59,600,000 [6] 32,000,000 263,851,000 212,464,000 215,920,000
Long-lived assets 1,750,700,000       1,742,200,000       1,750,700,000 1,742,200,000 1,838,400,000
U.S
                      
Geographic information                      
Product, net                 3,581,000,000 2,176,800,000 1,954,800,000
Revenues from unconsolidated joint business                 1,087,300,000 1,033,300,000 878,800,000
Other revenues from external customers                 193,500,000 170,200,000 187,000,000
Long-lived assets 984,400,000       996,600,000       984,400,000 996,600,000 1,012,500,000
Europe
                      
Geographic information                      
Product, net                 1,170,200,000 [7] 1,216,200,000 [7] 1,163,300,000 [7]
Revenues from unconsolidated joint business                 1,600,000 [7] 14,300,000 [7] 29,900,000 [7]
Other revenues from external customers                 26,100,000 [7] 27,900,000 [7] 28,300,000 [7]
Long-lived assets 758,300,000 [7]       738,600,000 [7]       758,300,000 [7] 738,600,000 [7] 816,600,000 [7]
Germany
                      
Geographic information                      
Product, net                 417,700,000 409,200,000 377,500,000
Revenues from unconsolidated joint business                 0 0 0
Other revenues from external customers                 1,200,000 1,100,000 600,000
Long-lived assets 2,500,000       1,900,000       2,500,000 1,900,000 1,600,000
Asia
                      
Geographic information                      
Product, net                 93,200,000 93,200,000 88,700,000
Revenues from unconsolidated joint business                 3,200,000 27,500,000 30,700,000
Other revenues from external customers                 43,100,000 13,300,000 0
Long-lived assets 2,100,000       2,900,000       2,100,000 2,900,000 5,300,000
Other
                      
Geographic information                      
Product, net                 280,200,000 270,700,000 251,800,000
Revenues from unconsolidated joint business                 33,900,000 62,800,000 57,200,000
Other revenues from external customers                 0 0 0
Long-lived assets $ 3,300,000       $ 2,200,000       $ 3,300,000 $ 2,200,000 $ 2,400,000
[1] Net income and net income attributable to Biogen Idec Inc. for the first quarter of 2012 includes a charge to research and development expense of $29.0 million related to an upfront payment made in connection with our development agreement entered into with Isis.
[2] Net income and net income attributable to Biogen Idec Inc., for the third quarter of 2013, includes a charge to research and development expense of $75.0 million related to an upfront payment made in connection with our collaboration agreement entered into with Isis.
[3] Product revenues and total revenues for the second, third and fourth quarters of 2013 includes 100% of net revenues related to sales of TYSABRI as a result of our acquisition of TYSABRI rights from Elan on April 2, 2013 and net revenues related to sales of TECFIDERA, our new oral first-line treatment for people with relapsing forms of multiple sclerosis (MS), which was approved by the FDA in March 2013 and commenced commercial sales in April 2013.
[4] Our share of revenues from unconsolidated joint business reflects a charge of $41.5 million for damages and interest awarded to Hoechst in Genentech's arbitration with Hoechst for RITUXAN.
[5] Net income and net income attributable to Biogen Idec Inc. for the fourth quarter of 2012 includes the correction of an error that had accumulated over several prior years in our deferred tax accounting for capitalized interest which resulted in an expense of $29.0 million.
[6] Net income and net income attributable to Biogen Idec Inc. for the fourth quarter of 2012 includes a charge to research and development expense of $30.0 million related to an upfront payment made in connection with our development agreement entered into with Isis.
[7] Represents amounts related to Europe less those attributable to Germany.